Skip to content

Investigation of the effect of organic light-emitting diode illumination on melatonin secretion.

Investigation of the effect of organic light-emitting diode (OLED) illumination on melatonin secretion. - Investigation of the effect of organic light-emitting diode (OLED) illumination on melatonin secretion.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050321
Enrollment
25
Registered
2023-02-13
Start date
2023-02-13
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult

Interventions

The patients will be irradiated (at rest) in the test lighting environment for 300 minutes, during which melatonin samples will be taken every 30 minutes and PVT will be performed every 60 minutes. Th

Sponsors

KANEKA CORPORATION
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Japanese males aged 18 to 35 years old. 2) Healthy subjects not receiving any medical treatment 3) No medication use. 4) Not taking any sleeping supplements 5) Not engaged in night shift/shift work 6) Habitual sleeping hours of 7 to 9 hours 7) Those whose habitual bedtime is between 23:00 and 25:00 8) Able to make designated visits and fill in records 9) The subject must have given written consent to this study.

Exclusion criteria

Exclusion criteria: 1) With ophthalmologic disease 2) PSQI more than 6 3) BMI more than 25 4) MEQ 30 or less or MEQ more than70 5) Patients who need dental treatment 6) Those with irregular lifestyle 7) AUDIT more than 15 8) Smokers 9-1) Those who cannot refrain from taking food for specified health use, functional foods, or other so-called health foods during the study period 9-2) Those who are unable to refrain from taking foods for specified health use, foods with functional claims, or other so-called health foods during the test period 10) Those who have traveled to time zone within the last 1 month. 11) Those who are allergic to metals 12) Those who cannot stop consuming caffeine or alcohol during the study period. 13) Patients with mental illness 14) Participation in other clinical trials *Last 1 month

Design outcomes

Primary

MeasureTime frame
melatonin suppression

Secondary

MeasureTime frame
Melatonin concentration, melatonin onset, Sleep indices (sleep efficiency, sleep latency, sleep depth, arousal during sleep wake after sleep onset, sleepiness (reaction rate, response rate, variability of response rate, correct response rate), autonomic nervous system (autonomic balance, parasympathetic nervous system activity)

Countries

Japan

Contacts

Public ContactNaomi ADACHI

Medithink,Inc. none

adachi@medithink.co.jp03-6459-3960

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026